PEPTIDE DENDRIMERS
Peptide Dendrimers - A Chemical Platform for Functional Diversity
| Coordinatore | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)
Organization address
address: CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA contact info |
| Nazionalità Coordinatore | Spain [ES] |
| Totale costo | 240˙817 € |
| EC contributo | 240˙817 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2009-IOF |
| Funding Scheme | MC-IOF |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-06-13 - 2014-06-12 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)
Organization address
address: CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA contact info |
ES (BARCELONA) | coordinator | 240˙817.90 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Peptides have emerged as a therapeutically important class of drugs and offer the advantage of great specificity, potency and low toxicity. Short circulation half-life, poor proteolytic stability and bioavailability have however prevented them from becoming a mainstream source of drug candidates. Dendrimers are versatile, derivatizable, well-defined branched synthetic macromolecules with promising properties for a variety of applications in technology and medicine. Combining therapeutic peptides with dendrimers represents a promising approach to overcome bioavailability limitations, while at the same time introducing novel pharmacological and biophysical properties. The impact of the dendritic structure and multivalency on potency, selectivity, bioavailability and overall pharmacology will be studied on nicotinic acetylcholine and oxytocin/vasopressin G-protein coupled receptors, two important biomedical targets. A synthetic strategy based on efficient ligation chemistry and combinatorial assembly of building blocks will form the platform for the assembly of diverse multifunctional peptide dendrimers. These peptide dendrimers will undergo detailed structural, biophysical and pharmacological characterization for their use as diagnostic tools and therapeutics.'
Introduzione (Teaser)
A new chemical methodology promises the production of non-toxic peptide dendrimers (PDs) with improved half-life and enhanced bioactivity.